Literature DB >> 3005468

Identification of a second class of IgG Fc receptors on human neutrophils. A 40 kilodalton molecule also found on eosinophils.

R J Looney, D H Ryan, K Takahashi, H B Fleit, H J Cohen, G N Abraham, C L Anderson.   

Abstract

We describe a newly recognized 40 kD FcR for IgG on human neutrophilic granulocytes. An mAb (IV3) developed against the IgG FcR of K562 cells, and specific as well for a 40 kD FcR on human monocytes and platelets, was found to purify by affinity adsorption a 40 kD protein from detergent lysates of surface-radioiodinated neutrophils. This protein, proteolytically degraded to 33 kD when purified in the absence of diisopropylfluorophosphate, is distinct from the 51-73 kD protein precipitated by the anti-neutrophil FcR mAb, 3G8, previously described by others. Complete inhibition of binding of rabbit IgG-coated erythrocytes to neutrophils was achieved only when both antibodies, IV3 and 3G8, were used. Fab fragments of IV3 were as effective inhibitors as the intact molecule. IV3 IgG or Fab fragments completely and selectively inhibited immune complex-mediated generation of superoxide by human neutrophils; superoxide generation by other stimulants was not abrogated by IV3. This antibody (IV3) bound also to human eosinophils and completely inhibited the binding of IgG-coated erythrocytes to eosinophils. IV3 appears to define the human homolog of the murine macrophage FcRII identified initially by mAb 2.4G2 and present in the mouse on both neutrophils and eosinophils.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005468      PMCID: PMC2188084          DOI: 10.1084/jem.163.4.826

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

1.  Activity and activation of the granulocyte superoxide-generating system.

Authors:  P E Newburger; M E Chovaniec; H J Cohen
Journal:  Blood       Date:  1980-01       Impact factor: 22.113

2.  Superoxide generation by digitonin-stimulated guinea pig granulocytes. A basis for a continuous assay for monitoring superoxide production and for the study of the activation of the generating system.

Authors:  H J Cohen; M E Chovaniec
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

Review 3.  Antibody-dependent cell-mediated cytolysis (ADCC): analyses and projections.

Authors:  J C Lovchik; R Hong
Journal:  Prog Allergy       Date:  1977

4.  The immunologic release of constituents from neutrophil leukocytes. I. The role of antibody and complement on nonphagocytosable surfaces or phagocytosable particles.

Authors:  P M Henson
Journal:  J Immunol       Date:  1971-12       Impact factor: 5.422

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Characterization of the interaction of human eosinophils and neutrophils with opsonized particles.

Authors:  M Yazdanbakhsh; C M Eckmann; D Roos
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

7.  Human neutrophils and eosinophils have structurally distinct Fc gamma receptors.

Authors:  A Kulczycki
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

8.  Interaction of cells with immune complexes: adherence, release of constituents, and tissue injury.

Authors:  P M Henson
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

9.  Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line.

Authors:  C H Heusser; C L Anderson; H M Grey
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

10.  Isolation of the receptor for IgG from a human monocyte cell line (U937) and from human peripheral blood monocytes.

Authors:  C L Anderson
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

View more
  42 in total

1.  Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function.

Authors:  J E Salmon; J C Edberg; N L Brogle; R P Kimberly
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

2.  The specificity of the human neutrophil IgA receptor (Fc alpha R) determined by measurement of chemiluminescence induced by serum or secretory IgA1 or IgA2.

Authors:  W W Stewart; M A Kerr
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

3.  The specificity of the IgA receptor purified from human neutrophils.

Authors:  R L Mazengera; M A Kerr
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

Review 4.  Function and heterogeneity of human Fc receptors for immunoglobulin G.

Authors:  J C Unkeless
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

5.  Identification of multiple isoforms of the low-affinity human IgG Fc receptor.

Authors:  T Seki
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

6.  Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study.

Authors:  D D Sedmak; D H Davis; U Singh; J G van de Winkel; C L Anderson
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

Review 7.  Surface proteins and glycoproteins of human leucocytes.

Authors:  V Horejsí; V Bazil
Journal:  Biochem J       Date:  1988-07-01       Impact factor: 3.857

Review 8.  Eosinophils. Assays and interpretation.

Authors:  D E Maddox
Journal:  Clin Rev Allergy       Date:  1988

9.  Isolation from human chronic-lymphocytic-leukaemia cells of membrane glycoproteins associated with Fc-receptor functions. Physical parameters and production of polyclonal antibodies.

Authors:  G Gorini; G A Medgyesi; M Garavini; K J Dorrington; J Down
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

10.  Fc gamma RI and Fc gamma RIII on polymorphonuclear leucocytes in cord blood.

Authors:  N Takahashi; H Nishida; T Kuratsuji
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-01       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.